Literature DB >> 11784835

Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naïve schizophrenic patients: correlations with symptom change.

E T C Ngan1, C J Lane, T J Ruth, P F Liddle.   

Abstract

OBJECTIVE: Different symptom patterns have been shown to be associated with specific patterns of cerebral metabolic activity in schizophrenia. Treatment with various neuroleptic drugs results in decreased metabolism in frontal cortical regions. The temporal and regional relation between changes in metabolism and symptom improvement after treatment with risperidone was studied in eight previously unmedicated schizophrenic patients.
METHOD: Cerebral metabolic activity was measured using PET before neuroleptic exposure, after the first dose of risperidone, and after 6 weeks of treatment. Pearson correlations were calculated for regions of significant change in metabolism and symptom change.
RESULTS: After 6 weeks of treatment significant deactivations were seen in the left lateral cortical frontal region and medial frontal cortex. Significant changes were detectable in the medial frontal region 90 minutes after the first dose of risperidone. Patients with higher baseline activity in the identified medial frontal cluster had higher baseline positive symptom scores and reduction in medial frontal metabolism was correlated with reduction in positive symptom score.
CONCLUSION: The evidence suggests that the reduction in medial-frontal activity after treatment with risperidone is a direct effect of risperidone and not a consequence of symptom improvement. Reduction of medial frontal metabolism may be one of the physiological mechanisms by which risperidone alleviates symptoms of psychosis in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11784835      PMCID: PMC1737716          DOI: 10.1136/jnnp.72.1.106

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  25 in total

1.  Detecting activations in PET and fMRI: levels of inference and power.

Authors:  K J Friston; A Holmes; J B Poline; C J Price; C D Frith
Journal:  Neuroimage       Date:  1996-12       Impact factor: 6.556

2.  Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients: a pilot study.

Authors:  I Berman; A Merson; C Sison; E Allan; C Schaefer; M Loberboym; M F Losonczy
Journal:  Psychopharmacol Bull       Date:  1996

3.  Clinical symptoms and regional cerebral blood flow in schizophrenia.

Authors:  S Yuasa; M Kurachi; M Suzuki; Y Kadono; M Matsui; O Saitoh; H Seto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

4.  Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naïve patients.

Authors:  N C Andreasen; D S O'Leary; M Flaum; P Nopoulos; G L Watkins; L L Boles Ponto; R D Hichwa
Journal:  Lancet       Date:  1997-06-14       Impact factor: 79.321

5.  Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol.

Authors:  H H Holcomb; N G Cascella; G K Thaker; D R Medoff; R F Dannals; C A Tamminga
Journal:  Am J Psychiatry       Date:  1996-01       Impact factor: 18.112

6.  The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task.

Authors:  R M Cohen; T E Nordahl; W E Semple; P Andreason; R E Litman; D Pickar
Journal:  Arch Gen Psychiatry       Date:  1997-05

7.  Clozapine effects on glucose metabolic rate in striatum and frontal cortex.

Authors:  S G Potkin; M S Buchsbaum; Y Jin; C Tang; J Telford; G Friedman; S Lottenberg; A Najafi; B Gulasekaram; J Costa
Journal:  J Clin Psychiatry       Date:  1994-09       Impact factor: 4.384

8.  Antipsychotic drug-induced dysphoria.

Authors:  D J King; M Burke; R A Lucas
Journal:  Br J Psychiatry       Date:  1995-10       Impact factor: 9.319

9.  Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

Authors:  C M Beasley; G Tollefson; P Tran; W Satterlee; T Sanger; S Hamilton
Journal:  Neuropsychopharmacology       Date:  1996-02       Impact factor: 7.853

10.  Symptoms of schizophrenia. Methods, meanings, and mechanisms.

Authors:  N C Andreasen; S Arndt; R Alliger; D Miller; M Flaum
Journal:  Arch Gen Psychiatry       Date:  1995-05
View more
  17 in total

1.  Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia.

Authors:  Carol J Lane; Elton T C Ngan; Lakshmi N Yatham; Tom J Ruth; Peter F Liddle
Journal:  J Psychiatry Neurosci       Date:  2004-01       Impact factor: 6.186

2.  Limbic activity in antipsychotic naïve first-episode psychotic subjects during facial emotion discrimination.

Authors:  Daniel Bergé; Susanna Carmona; Purificación Salgado; Mariana Rovira; Antoni Bulbena; Oscar Vilarroya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11-21       Impact factor: 5.270

3.  Impact of antipsychotic treatment on attention and motor learning systems in first-episode schizophrenia.

Authors:  Sarah K Keedy; James L Reilly; Jeffrey R Bishop; Peter J Weiden; John A Sweeney
Journal:  Schizophr Bull       Date:  2014-06-03       Impact factor: 9.306

4.  Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study.

Authors:  M Soyka; W Koch; H J Möller; T Rüther; K Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04-18       Impact factor: 5.270

5.  Antagonism at serotonin 5-HT(2A) receptors modulates functional activity of frontohippocampal circuit.

Authors:  Alessandro Gozzi; Valerio Crestan; Giuliano Turrini; Marcel Clemens; Angelo Bifone
Journal:  Psychopharmacology (Berl)       Date:  2010-01-29       Impact factor: 4.530

6.  Topographic analysis of individual activation patterns in medial frontal cortex in schizophrenia.

Authors:  Emily R Stern; Robert C Welsh; Kate D Fitzgerald; Stephan F Taylor
Journal:  Hum Brain Mapp       Date:  2009-07       Impact factor: 5.038

Review 7.  Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia.

Authors:  Stacy A Castner; Patricia S Goldman-Rakic; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

8.  An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia.

Authors:  Sarah K Keedy; Cherise Rosen; Tin Khine; Rajaprabhakaran Rajarethinam; Philip G Janicak; John A Sweeney
Journal:  Psychiatry Res       Date:  2009-02-24       Impact factor: 3.222

9.  Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain.

Authors:  Rowena Handley; Fernando O Zelaya; A A T Simone Reinders; Tiago Reis Marques; Mitul A Mehta; Ruth O'Gorman; David C Alsop; Heather Taylor; Atholl Johnston; Steve Williams; Philip McGuire; Carmine M Pariante; Shitij Kapur; Paola Dazzan
Journal:  Hum Brain Mapp       Date:  2012-03-25       Impact factor: 5.038

10.  Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia.

Authors:  Adrienne C Lahti; Martin A Weiler; Henry H Holcomb; Carol A Tamminga; Karen L Cropsey
Journal:  Neuropsychopharmacology       Date:  2009-08-12       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.